News

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...
Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...
Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...
The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...
Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...